Oommen, Deepu and Kizhakkedath, Praseetha and Jawabri, Aseel A. and Varghese, Divya Saro and Ali, Bassam R. (2020) Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia. Frontiers in Genetics, 11. ISSN 1664-8021
![[thumbnail of pubmed-zip/versions/1/package-entries/fgene-11-570355/fgene-11-570355.pdf]](http://publish7promo.com/style/images/fileicons/text.png)
pubmed-zip/versions/1/package-entries/fgene-11-570355/fgene-11-570355.pdf - Published Version
Download (2MB)
Abstract
Familial hypercholesterolemia (FH) is an autosomal genetic disease characterized by high serum low-density lipoprotein (LDL) content leading to premature coronary artery disease. The main genetic and molecular causes of FH are mutations in low-density lipoprotein receptor gene (LDLR) resulting in the non-clearance of LDL from the blood by hepatocytes and consequently the formation of plaques. LDLR is synthesized and glycosylated in the endoplasmic reticulum (ER) and then transported to the plasma membrane via Golgi. It is estimated that more than 50% of reported FH-causing mutations in LDLR result in misfolded proteins that are transport-defective and hence retained in ER. ER accumulation of misfolded proteins causes ER-stress and activates unfolded protein response (UPR). UPR aids protein folding, blocks further protein synthesis, and eliminates misfolded proteins via ER-associated degradation (ERAD) to alleviate ER stress. Various studies demonstrated that ER-retained LDLR mutants are subjected to ERAD. Interestingly, chemical chaperones and genetic or pharmacological inhibition of ERAD have been reported to rescue the transport defective mutant LDLR alleles from ERAD and restore their ER-Golgi transport resulting in the expression of functional plasma membrane LDLR. This suggests the possibility of pharmacological modulation of proteostasis in the ER as a therapeutic strategy for FH. In this review, we picture a detailed analysis of UPR and the ERAD processes activated by ER-retained LDLR mutants associated with FH. In addition, we discuss and critically evaluate the potential role of chemical chaperones and ERAD modulators in the therapeutic management of FH.
Item Type: | Article |
---|---|
Subjects: | Euro Archives > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 28 Feb 2023 08:11 |
Last Modified: | 13 Feb 2024 03:47 |
URI: | http://publish7promo.com/id/eprint/1927 |